New GlobalData Pharma Benchmark Report Addresses Lack of Strategic Intelligence Solutions07 Aug 2012 • by Natalie Aster
As emerging economies and medical advances continue to broaden the healthcare landscape, pharmaceutical market observers are finding there’s a lack of strategic intelligence that accounts for an increasingly diverse industry — a problem that hopes to provide a solution to with its new report series.
Latest release, "Pharmaceutical Leaders 2012 - Key Trends, Emerging Strategies and Financial Analysis of the Top Performers" provided by GlobalData is the first in a series of annual reports completed by its newly established Boston, Massachusetts, Industry Dynamics Team.
GlobalData’s 2012 Pharmaceutical Benchmark Report addresses the current inadequacies in pharmaceutical analysis by providing in-depth analysis on the top 25 pharmaceutical companies from 2011 by therapy area and region, offering a new and actionable perspective on what has become an outdated understanding of what makes a successful business model.
Pharmaceutical Leaders 2012 - Key Trends, Emerging Strategies and Financial Analysis of the Top Performers
Published: July, 2012
Price: US$ 5.700,00
GlobalData’s analyst for healthcare industry dynamics and author of the report, Adam Dion, MS, said: “There is no one-size-fits-all strategy for success in the pharmaceutical industry. Rather, each successful company uses its own mixture of business approaches to attempt to optimize achievement in particular therapeutic or geographic areas”.
“Focusing on top-line revenues or market share gives an incomplete picture of successful pharmaceutical enterprises. By looking at margins, growth and penetration into new markets, we can gain a more comprehensive understanding of the most successful companies.”
GlobalData’s proprietary ranking system revealed that the top performing pharmaceutical company in 2011 was Merck & Co., with other leading performances from companies such as Novartis, Celgene, Teva Pharmaceuticals, Roche and Novo Nordisk.
The report provides comprehensive analysis on the key issues affecting the industry, such as the need to find innovate strategies to compensate from losses stemming from the patent cliff and the rise of the BRIC nations, and how leading companies have adapted and excelled. Key drivers and trends across all traditional and developing economies are explored, along with detailed assessments of the leading drug manufacturers in the six major therapeutic areas of cardiovascular diseases, central nervous system (CNS), diabetes and metabolics, immunology, oncology, and respiratory diseases
More information can be found in the report “Pharmaceutical Leaders 2012 - Key Trends, Emerging Strategies and Financial Analysis of the Top Performers” by GlobalData.
To order the report or ask for sample pages contact firstname.lastname@example.org